The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in patients with eosinophilic esophagitis at 24 weeks, a randomized phase III ...
Please provide your email address to receive an email when new articles are posted on . The impact of food elimination diets on medication previously was unknown. Absolute mean changes in Dysphagia ...
Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear. In a phase 3, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results